Biomarkers of Residual Disease, Disseminated Tumor Cells, and Metastases in the MMTV-PyMT Breast Cancer Model
Open Access
- 8 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3), e58183
- https://doi.org/10.1371/journal.pone.0058183
Abstract
Cancer metastases arise in part from disseminated tumor cells originating from the primary tumor and from residual disease persisting after therapy. The identification of biomarkers on micro-metastases, disseminated tumors, and residual disease may yield novel tools for early detection and treatment of these disease states prior to their development into metastases and recurrent tumors. Here we describe the molecular profiling of disseminated tumor cells in lungs, lung metastases, and residual tumor cells in the MMTV-PyMT breast cancer model. MMTV-PyMT mice were bred with actin-GFP mice, and focal hyperplastic lesions from pubertal MMTV-PyMT;actin-GFP mice were orthotopically transplanted into FVB/n mice to track single tumor foci. Tumor-bearing mice were treated with TAC chemotherapy (docetaxel, doxorubicin, cyclophosphamide), and residual and relapsed tumor cells were sorted and profiled by mRNA microarray analysis. Data analysis revealed enrichment of the Jak/Stat pathway, Notch pathway, and epigenetic regulators in residual tumors. Stat1 was significantly up-regulated in a DNA-damage-resistant population of residual tumor cells, and a pre-existing Stat1 sub-population was identified in untreated tumors. Tumor cells from adenomas, carcinomas, lung disseminated tumor cells, and lung metastases were also sorted from MMTV-PyMT transplant mice and profiled by mRNA microarray. Whereas disseminated tumors cells appeared similar to carcinoma cells at the mRNA level, lung metastases were genotypically very different from disseminated cells and primary tumors. Lung metastases were enriched for a number of chromatin-modifying genes and stem cell-associated genes. Histone analysis of H3K4 and H3K9 suggested that lung metastases had been reprogrammed during malignant progression. These data identify novel biomarkers of residual tumor cells and disseminated tumor cells and implicate pathways that may mediate metastasis formation and tumor relapse after therapy.Keywords
This publication has 74 references indexed in Scilit:
- Disseminated tumor cells predict survival after neoadjuvant therapy in primary breast cancerCancer, 2011
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid TumorsCancer Cell, 2009
- GATA-3 Links Tumor Differentiation and Dissemination in a Luminal Breast Cancer ModelCancer Cell, 2008
- Systemic Spread Is an Early Step in Breast CancerCancer Cell, 2008
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006
- A collection of breast cancer cell lines for the study of functionally distinct cancer subtypesCancer Cell, 2006
- STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell linesInternational Journal of Cancer, 2006
- Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancerCancer Cell, 2005
- Solitary cancer cells as a possible source of tumour dormancy?Seminars in Cancer Biology, 2001